The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2023 | MinimuMM-seq: a novel, minimally invasive approach to characterize myeloma pathology
Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, briefly discusses a novel approach being explored to characterize multiple myeloma pathology, known as MinimuMM-seq. This minimally invasive approach provides details using whole-genome sequencing (WGS) without the need for bone marrow biopsy. This interview took place at the 9th World Congress on Controversies in Multiple Myeloma (COMy) 2023, held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
